A glance at molecular mechanisms underlying cisplatin-induced nephrotoxicity and possible renoprotective strategies: a narrative review

  • Bashar Adi Wahyu Pandhita Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Deliana Nur Ihsani Rahmi Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Nielda Kezia Sumbung Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Bernardino Matthew Waworuntu Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Regina Puspa Utami Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Melva Louisa Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0002-9451-0380
  • Vivian Soetikno Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
DOI: https://doi.org/10.13181/mji.v28i3.2690
Keywords: cisplatin, kidney, kidney injury, oxidative stress
Abstract viewed: 718 times
PDF downloaded: 667 times
HTML downloaded: 278 times
EPUB downloaded: 270 times

Abstract

Cisplatin is a platinum-based drug that is usually used for the treatment of many carcinomas. However, it comes with several devastating side effects, including nephrotoxicity. Cisplatin toxicity is a very complex process, which is exacerbated by the accumulation of cisplatin in renal tubular cells via passive diffusion and transporter-mediated processes. Once cisplatin enters these cells, it induces the formation of reactive oxygen species that cause cellular damage, including DNA damage, inflammation, and eventually cell death. On a small scale, these damages can be mitigated by cellular antioxidant defense mechanism. However, on a large scale, such as in chemotherapy, this defense mechanism may fail, resulting in nephrotoxicity. The current article reviews the molecular mechanisms underlying cisplatin-induced nephrotoxicity and possible renoprotective strategies to determine novel therapeutic interventions for alleviating this toxicity.

References

  1. Yang Y, Liu H, Liu F, Dong Z. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Arch Toxicol. 2014;88(6):1249-56. https://doi.org/10.1007/s00204-014-1239-1

  2. Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev. 2015;16(3):1117-22. https://doi.org/10.7314/APJCP.2015.16.3.1117

  3. Walker RJ, Endre ZH. Cellular mechanism of drug nephrotoxicity. In: Alpern RJ, Moe OR, Caplan MJ. Seldin and Giebisch's the kidney. 5th ed. 2013; Philadelphia: Saunders Elsevier. p.2889-932. https://doi.org/10.1016/B978-0-12-381462-3.00085-9

  4. Pourahmad J, Hosseini MJ, Eskandari MR, Shekarabi SM, Daraei B. Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica. 2010;40(11):763-71. https://doi.org/10.3109/00498254.2010.512093

  5. Zsengellér ZK, Ellezian L, Brown D, Horváth B, Mukhopadhyay P, Kalyanaraman B, et al. Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity. J Histochem Cytochem. 2012;60(7):521-9. https://doi.org/10.1369/0022155412446227

  6. Zhang JG, Lindup WE. Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol. 1993;45(11):2215-22. https://doi.org/10.1016/0006-2952(93)90192-Y

  7. Sari SD, Maknun LU, Louisa M, Estuningtyas A, Soetikno V. Effects of nanocurcumin against cisplatin-induced nephrotoxicity in rats. Adv Sci Lett. 2017;23(7):6823-7. https://doi.org/10.1166/asl.2017.9407

  8. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther. 1997;280(2):638-49.

  9. Santos NA, Catão CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81(7):495-504. https://doi.org/10.1007/s00204-006-0173-2

  10. Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci. 2006;100(1):65-72. https://doi.org/10.1254/jphs.FP0050661

  11. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanism of action. Eur J Pharmacol. 2014;740:364-78. https://doi.org/10.1016/j.ejphar.2014.07.025

  12. Basnakian AG, Apostolov EO, Yin X, Napirei M, Mannherz HG, Shah SV. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol. 2005;16(3):697-702. https://doi.org/10.1681/ASN.2004060494

  13. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2007;283(10):6572-83. https://doi.org/10.1074/jbc.M707568200

  14. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells. Kidney Int. 2007;72(1):37-44. https://doi.org/10.1038/sj.ki.5002242

  15. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6(4):224-35. https://doi.org/10.1038/nrneph.2010.16

  16. Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 1999;56(3):922-31. https://doi.org/10.1046/j.1523-1755.1999.00629.x

  17. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;60(6):2118-28. https://doi.org/10.1046/j.1523-1755.2001.00043.x

  18. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110(6):835-42. https://doi.org/10.1172/JCI200215606

  19. Mahgoub E, Kumaraswamy SM, Kader KH, Venkataraman B, Ojha S, Adeghate E, et al. Genipin attenuates cisplatin-induced nephrotoxicity by counteracting oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2017;93:1083-97. https://doi.org/10.1016/j.biopha.2017.07.018

  20. Soetikno V, Sari SD, Maknun LU, Sumbung NK, Rahmi DN, Pandhita BA, et al. Pre-treatment with curcumin ameliorates cisplatin-induced kidney damage by suppressing kidney inflammation and apoptosis in rats. Drug Res. 2018;69(2):75-82. https://doi.org/10.1055/a-0641-5148

  21. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int. 2004;65(2):490-8. https://doi.org/10.1111/j.1523-1755.2004.00413.x

  22. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005;289(1):F166-74. https://doi.org/10.1152/ajprenal.00401.2004

  23. Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, et al. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptorselective TNF-α mutants. EMBO J. 1994;13(4):843-50. https://doi.org/10.1002/j.1460-2075.1994.tb06327.x

  24. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501. https://doi.org/10.1016/S0092-8674(01)00237-9

  25. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 2003;285(4):F610-8. https://doi.org/10.1152/ajprenal.00101.2003

  26. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8(4):279-89. https://doi.org/10.1038/nri2215

  27. Cunningham PN, Wang Y, Guo R, He G, Quigg RJ. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol. 2004;172(4):2629-35. https://doi.org/10.4049/jimmunol.172.4.2629

  28. Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am J Physiol Renal Physiol. 2007;293(1):F325-32. https://doi.org/10.1152/ajprenal.00158.2007

  29. Ramesh G, Kimball SR, Jefferson LS, Reeves WB. Endotoxin and cisplatin synergistically stimulate TNF-α production by renal epithelial cells. Am J Physiol Renal Physiol. 2007;292(2):F812-9. https://doi.org/10.1152/ajprenal.00277.2006

  30. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol. 2008;19(5):923-32. https://doi.org/10.1681/ASN.2007090982

  31. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med. 2007;204(12):2913-23. https://doi.org/10.1084/jem.20070247

  32. Lieberthal W, Triaca V, Levine J. Mechanism of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 1996;270 (4):F700-8. https://doi.org/10.1152/ajprenal.1996.270.4.F700

  33. Hong JY, Kim GH, Kim JW, Kwon SS, Sato EF, Cho KH, et al. Computational modeling of apoptotic signaling pathways induced by cisplatin. BMC Syst Biol. 2012;6:122. https://doi.org/10.1186/1752-0509-6-122

  34. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 2003;63(1):72-82. https://doi.org/10.1046/j.1523-1755.2003.00709.x

  35. Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2007;293(4):F1282-91. https://doi.org/10.1152/ajprenal.00230.2007

  36. Tsuruya K, Yotsueda H, Ikeda H, Taniguchi M, Masutani K, Hayashida H, et al. Involvement of p53-transactivated Puma in cisplatin-induced renal tubular cell death. Life Sci. 2008;83(151-6):550-6. https://doi.org/10.1016/j.lfs.2008.08.002

  37. Zhang D, Liu Y, Wei Q, Huo Y, Liu K, Liu F, et al. Tubular p53 regulates multiple genes to mediate AKI. J Am Soc Nephrol. 2014;25(10):2278-89. https://doi.org/10.1681/ASN.2013080902

  38. Follis AV, Chipuk JE, Fisher JC, Yun MK, Grace CR, Nourse A, et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat Chem Biol. 2013;9(3):163-8. https://doi.org/10.1038/nchembio.1166

  39. di Pietro A, Koster R, Boersma-van Eck W, Dam WA, Mulder NH, Gietema JA, et al. Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell contextdependent. Cell Cycle. 2012;11(24):4552-62. https://doi.org/10.4161/cc.22803

  40. Hodeify R, Tarcsafalvi A, Megyesi J, Safirstein RL, Price PM. Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity. Am J Physiol Renal Physiol. 2011;300(5):F1171-9. https://doi.org/10.1152/ajprenal.00507.2010

  41. Kawai Y, Tainuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull. 2005;28(8):1385-8. https://doi.org/10.1248/bpb.28.1385

  42. Esteban-Fernández D, Verdaguer JM, Ramírez-Camacho R, Palacios MA, Gómez-Gómez MM. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol. 2008;32(2):140-6. https://doi.org/10.1093/jat/32.2.140

  43. Kröning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol. 2000;45(1):43-9. https://doi.org/10.1007/PL00006741

  44. Endo T, Kimura O, Sakata M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology. 2000;146(2-3):187-95. https://doi.org/10.1016/S0300-483X(00)00176-1

  45. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F505-11. https://doi.org/10.1152/ajprenal.90545.2008

  46. Jacobs C, Kalman SM, Tretton M, Weiner MW. Renal handling of cis-diamminedichloroplatinum (II). Cancer Treat Rep. 1980;64(12):1223-6.

  47. Osman NM, Litterst CL. Effect of probenecid and N'-methylnicotinamide on renal handling of cisdichlorodiammineplatinum-II in rats. Cancer Lett. 1983;19(1):107-11. https://doi.org/10.1016/0304-3835(83)90143-X

  48. Bird JE, Walser MM, Quebbemann AJ. Protective effect of organic cation transport inhibitors on cis-diamminedichloroplatinum induced nephrotoxicity. J Pharmacol Exp Ther. 1984;231(3):752-8.

  49. Klein J, Bentur Y, Cheung D, Moselhy G, Koren G. Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin Invest Med. 1991;14(5):388-94.

  50. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871-81. https://doi.org/10.1089/dna.1997.16.871

  51. Ciarimboli G, Ludwig T, Lang D, Pavenstäd H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167(6):1477-84. https://doi.org/10.1016/S0002-9440(10)61234-5

  52. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99(22):14298-302. https://doi.org/10.1073/pnas.162491399

  53. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol. 2008;294(4):F777-87. https://doi.org/10.1152/ajprenal.00590.2007

  54. Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol. 2012;180(2):517-25. https://doi.org/10.1016/j.ajpath.2011.11.001

  55. Zhang D, Pan J, Xiang X, Liu Y, Dong G, Livingston MJ, et al. Protein kinase cδ suppresses autophagy to induce kidney cell apoptosis in cisplatin nephrotoxicity. J Am Soc Nephrol. 2017;28(4):1131-44. https://doi.org/10.1681/ASN.2016030337

  56. Zhao C, Chen Z, Xu X, An X, Duan S, Huang Z, et al. Pink1/Parkin-mediated mitophagy play a protective role in cisplatin induced renal tubular epithelial cells injury. Exp Cell Res. 2017;350(2):390-7. https://doi.org/10.1016/j.yexcr.2016.12.015

  57. Wilmes A, Bielow C, Ranninger C, Bellwon P, Aschauer L, Limonciel A, et al. Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015;30(1 Pt A):117-27. https://doi.org/10.1016/j.tiv.2014.10.006

Published
2019-10-04
How to Cite
1.
Pandhita BAW, Rahmi DNI, Sumbung NK, Waworuntu BM, Utami RP, Louisa M, Soetikno V. A glance at molecular mechanisms underlying cisplatin-induced nephrotoxicity and possible renoprotective strategies: a narrative review. Med J Indones [Internet]. 2019Oct.4 [cited 2024Apr.24];28(3):292-9. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2690
Issue
Vol. 28 No. 3 (2019): September
Section
Review Article

Copyright (c) 2019 Bashar Adi Wahyu Pandhita, Deliana Nur Ihsani Rahmi, Bernardino Matthew Waworuntu, Regina Puspa Utami, Melva Louisa, Vivian Soetikno

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

Most read articles by the same author(s)